Co-Diagnostics Inc

C97

Company Profile

  • Business description

    Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

  • Contact

    2401 South Foothill Drive
    Salt Lake CityUT84109
    USA

    T: +1 801 438-1036

    https://www.codiagnostics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2025

    Employees

    132

Stocks News & Analysis

stocks

Undervalued ASX listed payment provider

Strong start to the new fiscal year.
stocks

Overpriced ASX listed consumer electronics retailers

Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks

Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs

Our update on select stocks from the Semiconductors industry.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,926.9036.000.40%
CAC 408,099.473.040.04%
DAX 4023,767.9641.740.18%
Dow JONES (US)47,427.121,181.712.56%
FTSE 1009,693.932.350.02%
HKSE25,945.9317.850.07%
NASDAQ23,214.69189.100.82%
Nikkei 22550,062.67104.43-0.21%
NZX 50 Index13,456.0923.890.18%
S&P 5006,812.6146.730.69%
S&P/ASX 2008,625.4033.600.39%
SSE Composite Index3,875.2611.080.29%

Market Movers